Keyphrases
Randomized Controlled Trial
100%
Pre-diabetes (pre-DM)
79%
Overweight or Obesity
63%
Obesity
58%
Metformin
42%
Leisure-time Exercise
41%
Active Commuting
37%
Vigorous Intensity
37%
Type 2 Diabetes Risk
37%
Hemoglobin A1c (HbA1c)
34%
Liraglutide
32%
Cardiorespiratory Fitness
30%
Dapagliflozin
29%
Type 2 Diabetes Mellitus (T2DM)
29%
Insulin Sensitivity
28%
Commute Time
27%
Exercise Group
26%
Physical Activity
26%
Time-restricted Feeding
25%
Cardiometabolic Health
25%
Exercise Effect
24%
VO2peak
23%
Placebo
23%
Structured Exercise
23%
Healthy Weight
23%
Single Center
23%
Growth Differentiation factor-15 (GDF-15)
23%
Exercise Training
23%
Weight Maintenance
23%
Moderate Intensity
20%
Oral Glucose Tolerance Test
20%
Body Composition
19%
Glucagon-like
17%
Receptor Agonist
17%
A1 Receptor
17%
Health Effects
17%
Per-protocol Analysis
16%
Weight Loss
15%
Exercise Affect
15%
Active Leisure
15%
Glucose-lowering Drugs
14%
Glycemic Variability
14%
Gastric Emptying
14%
Exercise Intervention
14%
Obese Men
14%
Physically Inactive
14%
Bike
14%
Exercise Intensity
13%
Abdominal Fat
13%
Metformin Treatment
13%
Medicine and Dentistry
Impaired Glucose Tolerance
79%
Randomized Controlled Trial
63%
Maturity Onset Diabetes of the Young
53%
Glycon
50%
Post-Hoc Analysis
46%
Obesity
39%
Hemoglobin A1c
35%
Liraglutide
31%
Body Weight
28%
Placebo
27%
Dapagliflozin
27%
Body Mass Index
24%
Glucagon-Like Peptide-1 Agonist
23%
Glycemic
19%
Oral Glucose Tolerance Test
18%
Arm
17%
Physical Activity
17%
Diabetes
15%
Insulin Sensitivity
15%
Biological Marker
15%
Exercise
13%
Cardiovascular Disease
13%
Antidiabetic Agent
13%
Glucagon
12%
Skeletal Muscle
11%
Hepcidin
11%
Metabolic Syndrome
11%
Extracellular Matrix
11%
Muscle Protein
11%
Microalbuminuria
11%
Diabetic Nephropathy
11%
Interstitial Fluid
11%
Glucose Intake
11%
Abdominal Obesity
11%
Protein Expression
11%
Energy Balance
11%
Growth Differentiation Factor 15
11%
Glycemic Control
11%
Carbohydrate Counting
11%
Drug Therapy
11%
Adverse Event
9%
Glycated Hemoglobin
9%
Pyruvate Dehydrogenase
7%
Body Fat Percentage
7%
Cardiometabolic Risk
7%
Disease Exacerbation
6%
Open-Label Trial
6%
Glucose Metabolism
6%
Low Calorie Diet
6%
Glomerular Filtration Rate
5%
